Active substances
Beclometasone + Formoterol
- SFDA 3
- NHS prices 4
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Bibecfo | 100,6 µg,µg | Pressurised inhalation, solution · Inhalation use | 1 Inhaler | SAR 72.05 | Generic · Prescription | Boston Oncology Arabia | Valid |
| FOSTER NEXTHALER 100MCG/6MCG INHALATION POWDER | 100,6 µg,µg | Inhalation powder · Inhalation use | 1 Multidose container | SAR 109.10 | NCE · Prescription | CHIESI FARMACEUTICIS | Valid |
| FOSTER PRESSURISED SOLUTION FOR INHALATION | 100,6 µg,µg | Pressurised inhalation, solution · Inhalation use | 1 Pressurised container | SAR 102.90 | Generic · Prescription | CHIESI FARMACEUTICIS | Valid |
Indications — CHI Daman Drug Formulary
ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Beclometasone 100micrograms/dose / Formoterol 6micrograms/dose dry powder inhaler | £29.32 | 120 dose | 1 Oct 2026 |
| NHS Drug Tariff | Beclometasone 100micrograms/dose / Formoterol 6micrograms/dose inhaler CFC free | £29.32 | 120 dose | 1 Oct 2026 |
| NHS Drug Tariff | Beclometasone 200micrograms/dose / Formoterol 6micrograms/dose dry powder inhaler | £29.32 | 120 dose | 1 Oct 2026 |
| NHS Drug Tariff | Beclometasone 200micrograms/dose / Formoterol 6micrograms/dose inhaler CFC free | £29.32 | 120 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease · core
Therapeutic equivalent to budesonide + formoterol for Asthma
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.